Cargando…

The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients

BACKGROUND: Hormone receptor (HR) and human epidermal growth factor receptor (HER2) discordance between primary and metastatic breast cancer lesions is common. However, its impact on long-term survival remains unclear. We aimed to determine the prognostic value of this discordance in patients with m...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ziyan, Li, Nani, Li, Xiaolin, Lei, Lei, Wang, Xiaojia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996483/
https://www.ncbi.nlm.nih.gov/pubmed/32099389
http://dx.doi.org/10.2147/OTT.S231493
_version_ 1783493522646630400
author Yang, Ziyan
Li, Nani
Li, Xiaolin
Lei, Lei
Wang, Xiaojia
author_facet Yang, Ziyan
Li, Nani
Li, Xiaolin
Lei, Lei
Wang, Xiaojia
author_sort Yang, Ziyan
collection PubMed
description BACKGROUND: Hormone receptor (HR) and human epidermal growth factor receptor (HER2) discordance between primary and metastatic breast cancer lesions is common. However, its impact on long-term survival remains unclear. We aimed to determine the prognostic value of this discordance in patients with metastaticf breast cancer (MBC). METHODS: A total of 270 patients with MBC who were underwent re-biopsy of progressive metastases at Zhejiang Cancer Hospital from January 1, 2012 to December 31, 2015 with patients consent and then review their primary tumors pathological findings. The HR and HER2 status in both primary and progressive metastatic lesions was determined by immunohistochemistry and/or fluorescence in situ hybridization. The discordance rates were correlated with the clinicopathologic characteristics, metastatic lesions, salvage treatment, and survival analysis in this population. RESULTS: A total of 142 (52.6%) MBC patients were diagnosed with discordant HR and HER2 status. Alterations in estrogen receptor (ER), progesterone receptor (PR), and HER2 status were observed in 20.70%, 37.78%, and 11.48% cases, respectively. Chemotherapy (P=0.0192) and endocrine therapy (P=0.048) significantly affected the conversion of HR status. Endocrine therapy was positively correlated with PR discordance (P=0.002), while ER discordance was associated with adjuvant chemotherapy (P=0.031). Survival analysis showed that ER status alterations between primary and metastatic lesions were associated with overall survival (P=0.002). The clinical prognosis was significantly worse with HR losses than with persistent HR positivity (P=0.023). In Cox multivariate analysis, the loss of HR expression and conversion to triple negative were independent prognostic indicators. CONCLUSION: Discordance in HR status between primary and metastatic lesions may impact the prognosis of MBC, and HR conversion has independent prognostic value.
format Online
Article
Text
id pubmed-6996483
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-69964832020-02-25 The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients Yang, Ziyan Li, Nani Li, Xiaolin Lei, Lei Wang, Xiaojia Onco Targets Ther Original Research BACKGROUND: Hormone receptor (HR) and human epidermal growth factor receptor (HER2) discordance between primary and metastatic breast cancer lesions is common. However, its impact on long-term survival remains unclear. We aimed to determine the prognostic value of this discordance in patients with metastaticf breast cancer (MBC). METHODS: A total of 270 patients with MBC who were underwent re-biopsy of progressive metastases at Zhejiang Cancer Hospital from January 1, 2012 to December 31, 2015 with patients consent and then review their primary tumors pathological findings. The HR and HER2 status in both primary and progressive metastatic lesions was determined by immunohistochemistry and/or fluorescence in situ hybridization. The discordance rates were correlated with the clinicopathologic characteristics, metastatic lesions, salvage treatment, and survival analysis in this population. RESULTS: A total of 142 (52.6%) MBC patients were diagnosed with discordant HR and HER2 status. Alterations in estrogen receptor (ER), progesterone receptor (PR), and HER2 status were observed in 20.70%, 37.78%, and 11.48% cases, respectively. Chemotherapy (P=0.0192) and endocrine therapy (P=0.048) significantly affected the conversion of HR status. Endocrine therapy was positively correlated with PR discordance (P=0.002), while ER discordance was associated with adjuvant chemotherapy (P=0.031). Survival analysis showed that ER status alterations between primary and metastatic lesions were associated with overall survival (P=0.002). The clinical prognosis was significantly worse with HR losses than with persistent HR positivity (P=0.023). In Cox multivariate analysis, the loss of HR expression and conversion to triple negative were independent prognostic indicators. CONCLUSION: Discordance in HR status between primary and metastatic lesions may impact the prognosis of MBC, and HR conversion has independent prognostic value. Dove 2020-01-28 /pmc/articles/PMC6996483/ /pubmed/32099389 http://dx.doi.org/10.2147/OTT.S231493 Text en © 2020 Yang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yang, Ziyan
Li, Nani
Li, Xiaolin
Lei, Lei
Wang, Xiaojia
The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients
title The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients
title_full The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients
title_fullStr The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients
title_full_unstemmed The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients
title_short The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients
title_sort prognostic impact of hormonal receptor and her-2 expression discordance in metastatic breast cancer patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996483/
https://www.ncbi.nlm.nih.gov/pubmed/32099389
http://dx.doi.org/10.2147/OTT.S231493
work_keys_str_mv AT yangziyan theprognosticimpactofhormonalreceptorandher2expressiondiscordanceinmetastaticbreastcancerpatients
AT linani theprognosticimpactofhormonalreceptorandher2expressiondiscordanceinmetastaticbreastcancerpatients
AT lixiaolin theprognosticimpactofhormonalreceptorandher2expressiondiscordanceinmetastaticbreastcancerpatients
AT leilei theprognosticimpactofhormonalreceptorandher2expressiondiscordanceinmetastaticbreastcancerpatients
AT wangxiaojia theprognosticimpactofhormonalreceptorandher2expressiondiscordanceinmetastaticbreastcancerpatients
AT yangziyan prognosticimpactofhormonalreceptorandher2expressiondiscordanceinmetastaticbreastcancerpatients
AT linani prognosticimpactofhormonalreceptorandher2expressiondiscordanceinmetastaticbreastcancerpatients
AT lixiaolin prognosticimpactofhormonalreceptorandher2expressiondiscordanceinmetastaticbreastcancerpatients
AT leilei prognosticimpactofhormonalreceptorandher2expressiondiscordanceinmetastaticbreastcancerpatients
AT wangxiaojia prognosticimpactofhormonalreceptorandher2expressiondiscordanceinmetastaticbreastcancerpatients